Destiny Pharma PLC Grant of Options (1162B)
June 04 2019 - 8:39AM
UK Regulatory
TIDMDEST
RNS Number : 1162B
Destiny Pharma PLC
04 June 2019
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Grant of Options
Brighton, United Kingdom - 4 June 2019 - Destiny Pharma (AIM:
DEST), a clinical stage biotechnology company focused on the
development of novel antimicrobial drugs, which address the global
problem of antimicrobial resistance (AMR), announces that it has
granted options ("Options") over 335,000 new ordinary shares of 1
pence each in the Company ("Ordinary Shares") (representing 0.76
per cent. of the Company's issued share capital) to certain
employees of the Company, including the below Director and
PDMR.
Name Position Options Issued Total Options
Held Post Issue
Chief Executive
Neil Clark Officer 200,000 544,305
Jesus Gonzales PDMR 75,000 75,000
The Options represent awards under the Destiny Pharma Employee
Long Term Incentive Plan 2018 approved by the Company on 25 January
2018 for EMI and non-tax advantage options. The Options have been
granted at a price of GBP0.01 per Ordinary Share, which will vest
on the third anniversary of the date of grant and are exercisable
for ten years thereafter.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0)20 3705 9321
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the WHO and
the United Nations, as well as the G7 and the G20 countries. For
further information, please visit https://www.destinypharma.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Neil Clark
------------------------------- ----------------------------------
2. Reason for the Notification
-------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- ----------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- ----------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- ----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
-------------------------------------------------------------------
a) Description of the Options over ordinary shares of
Financial instrument, 1 pence each ("Ordinary Shares")
type of instrument
Identification code DEST GB00BDHSP575
------------------------------- ----------------------------------
b) Nature of the transaction Grant of Options
------------------------------- ----------------------------------
c) Price(s) and volume(s) 1 pence per Ordinary Share
200,000 Ordinary Shares
------------------------------- ----------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
------------------------------- ----------------------------------
e) Date of the transaction 4 June 2019
------------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
------------------------------- ----------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Jesus Gonzales
------------------------------- ----------------------------------
2. Reason for the Notification
-------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- ----------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- ----------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- ----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
-------------------------------------------------------------------
a) Description of the Options over ordinary shares of
Financial instrument, 1 pence each ("Ordinary Shares")
type of instrument
Identification code DEST GB00BDHSP575
------------------------------- ----------------------------------
b) Nature of the transaction Grant of Options
------------------------------- ----------------------------------
c) Price(s) and volume(s) 1 pence per Ordinary Share
75,000 Ordinary Shares
------------------------------- ----------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
------------------------------- ----------------------------------
e) Date of the transaction 4 June 2019
------------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
------------------------------- ----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBXGDLLXGBGCS
(END) Dow Jones Newswires
June 04, 2019 09:39 ET (13:39 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024
